Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 9/20 | 0.63 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 5/20 | 0.34 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.31 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL350214 | 0.77 | LIPE (1.00) | LIPE | |
| SCHEMBL747930 | 0.68 | LIPE (0.44) | LIPEL3MBTL1SMN1; SMN2 | |
| SCHEMBL350263 | 0.64 | LIPE (1.00) | LIPE | |
| SCHEMBL746750 | 0.63 | CYP3A4 (0.44) | LIPESMN1; SMN2 | |
| SCHEMBL347868 | 0.62 | LIPE (1.00) | LIPE | |
| SCHEMBL3752081 | 0.60 | LIPE (0.58) | LIPE | |
| SCHEMBL3745559 | 0.60 | LIPE (0.59) | LIPEL3MBTL1 | |
| SCHEMBL364099 | 0.60 | SLC6A2 (0.44) | LIPESMN1; SMN2 | |
| SCHEMBL1146754 | 0.59 | EPHX2 (0.53) | LIPE | |
| SCHEMBL17543099 | 0.58 | NOTUM (0.43) | LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015970-A1 | NEW AZACYCLIC COMPOUNDS | AZI2, CDKN1A, TOP2B | LIPE 4875/4885ADAMTS4 3920/4885MMP13 3784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.